Navigation Links
Lung cancer risk particularly high for heart and liver transplant recipients
Date:5/1/2010

Heart and liver transplant recipients are at particularly high risk of developing lung cancer after receiving the donated organ, researchers report at the 2nd European Lung Cancer Conference. They are advising doctors to screen for such cancers in these patients to maximize the chance of detecting the malignancy early.

Doctors have known for decades that the immunosuppressive drugs given to transplant patients increase their risk of developing new cancers. In transplant patients, the risk of developing a malignant tumor ranges from 4% to 18% and may be 100-fold higher than in the general population. The most common malignancies after transplantation are cancers of the lips and skin, lymphoproliferative disorders and Kaposi's sarcoma.

In a new study, French researchers studied the risk of developing lung cancer in patients who received different types of solid organs. Theirs is the largest study to date exploring the development of lung cancer in transplant recipients.

The researchers followed a group of 2,831 patients who received organ transplants at Toulouse Hospital between February 1984 and September 2006. Overall, 0.85% of them developed a lung cancer after transplant.

"We observed that 10 lung cancers occurred after kidney transplantation (0.5%), 8 after liver transplantation (1.3%) and 6 after heart transplantation (2.8%). This difference is statistically significant," said Dr Julien Mazieres, the study coordinator.

"The high incidence of lung cancer in heart transplant and liver transplant recipients may be because more of these patients have a heavy smoking history compared to kidney transplant recipients," he said. The average number of packs per year was 75.2 for heart-transplant patients, 40 for liver-transplant recipients and 28.5 for kidney-transplant recipients.

The researchers say that transplant patients should be screened for expected cancers for which early detection and treatment is assoc
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
2. A study by the MUHC and McGill University opens a new door to understanding cancer
3. ESF EURYI award winner aims to stop cancer cells reading their own DNA
4. Protein chatter linked to cancer activation
5. Newly created cancer stem cells could aid breast cancer research
6. Western diet linked to increased risk of colon cancer recurrence
7. Obesity and lack of exercise could enhance the risk of pancreatic cancer
8. Low levels of key protein may indicate pancreatic cancer risk
9. Birth records hold pancreatic cancer clue
10. Many parents at-risk for cancer disclose genetic test results to children
11. A new radiation therapy treatment developed for head and neck cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications Corp. ... global provider of Software Defined Network Architecture (ET Software ... total revenue of approximately $20.4 million for the year ... $19.5 million for the year ended December 31, 2013. ... the Company had completed its multi-year transition away from ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ... Iris Recognition Market 2015-2019" report to their offering. ... market to grow at a CAGR of 23.5 percent ... the present scenario and the growth prospects of the ... calculate the market size, the report considers the revenue ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... doesn,t bed down with theatre, much less mate with ... explored in the recent production Heuschrecken [The Locusts] developed ... asks Arizona State University,s Manfred Laubichler and Gitta Honegger ... of the journal Science . "Scientists have ...
... WASHINGTON, Jan. 28, 2010 The U.S. Department ... the release of new satellite images depicting agricultural land ... crop year. The images, referred to as cropland data ... rotation patterns, land use changes, water resources and carbon ...
... The Genetics Society of America (GSA) is pleased ... distinguished service to the field of genetics. These ... the genetics community. The individuals who receive these ... recognition of the exceptional value of their work to ...
Cached Biology News:Scientists and cast of thousands swarm stage in Europe 2Scientists and cast of thousands swarm stage in Europe 3The Genetics Society of America announces its 2010 award recipients 2The Genetics Society of America announces its 2010 award recipients 3
(Date:5/5/2015)... TEL AVIV, Israel , May 5, 2015 ... that the Company was approved to continue trading ... companies. OTCQB Marketplace allows for ... an electronic broker-dealers. Investors can have real-time quotes ... The OTCQB Marketplace includes ...
(Date:5/5/2015)... , May 5, 2015  A group of biotechnology ... the Coma Research Institute, a non-profit organization dedicated to ... families suffering from disorders of consciousness.  ... http://photos.prnewswire.com/prnh/20150504/213779LOGO   ... consciousness, in which no voluntary actions can be initiated ...
(Date:5/5/2015)... Calif. , May 5, 2015 CytomX, ... of cancer, today announced that Sean McCarthy , ... Credit Suisse Antibody Day in New York ... 6. Dr. McCarthy will present an overview of CytomX,s ... Probody drug conjugate programs. About CytomX Therapeutics ...
(Date:5/5/2015)... -- Indianapolis-based medical device manufacturer NICO Corporation is seeing ... including the BrainPath® and Myriad™ technologies offering a ... and then removing affected tissue. More than 1,600 ... institutions throughout the United States ... 12 abstracts, three peer-reviewed publications, and seven presentations ...
Breaking Biology Technology:Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 2NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 3
... Drug Offers Potential Treatment ... to Americans Suffering from IBS-C, BETHESDA, Md., Sept. 17 ... the supplemental,New Drug Application (sNDA) for lubiprostone (8 mcg, oral ... with,constipation (IBS-C) has been accepted for review by the U.S. ...
... 17 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ) ... President, will present an overview of the Company,s ... Annual Investment Conference,in San Francisco. Dr. Henderson,s presentation ... am PT. Dr. Henderson,s presentation will be ...
... Tissue Provides Building-Block Cells for Muscle, Bone, ... ... BioLife Solutions,Inc. (OTC Bulletin Board: BLFS), a leading developer ... tissues, and organs, today announced that privately held Tissue,Regeneration Therapeutics ...
Cached Biology Technology:FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 2FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 3FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 4FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 5Keryx Biopharmaceuticals to Present at Bank of America Investment Conference 2BioLife Solutions' CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells 2BioLife Solutions' CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells 3
Edited by D. Patel (1994) Comprehensive data on gel electrophoresis of proteins, nucleic acids, nucleoproteins and carbohydrates....
...
... Silver Staining Kit, 1. Select from ... and peptides on denaturing, native, and ... reproducibility with precast gels, buffer strips, ... to that of radioisotopes with ready-to-use ...
Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
Biology Products: